Why API-First, and Why Now, in Regulated Pharma

The pharma-specific version of API-first has been slow to arrive, and the reasons are structural rather than technical. Validated systems change slowly on purpose. Interfaces to them tend to accrete rather than get refactored. A study team asks for a data feed, an integration is built, five years pass, the study ends, and the interface is still running. Nobody quite owns it, but nobody dares to touch it either.

The pressure to break this pattern is now coming from three directions at once. First, AI and analytics workloads demand clean, discoverable, well-documented APIs to access data and trigger actions autonomously.1 A model that cannot call your data reliably is a model that never leaves the pilot. Second, McKinsey’s research on biopharma R&D IT applications shows that modernization is now a competitive advantage, and companies that have not rationalized their applications are visibly slower to run trials.2 Third, the FDA finalized its Computer Software Assurance guidance in September 2025, formally endorsing risk-based, critical-thinking approaches that make it easier to justify modern architectures than the old proof-by-volume validation approach ever did.3

$60B-$110B Estimated value generative AI could create across pharma, dependent on accessible APIs2
70% Of enterprise new applications projected to use low-code or no-code by 2026, all of which run on APIs4
60-70% Reduction in post-migration incidents for phased strangler-pattern modernization vs. big-bang replacements5

Deloitte’s technical-debt research puts the cost side of this equation in equally clear terms. Life sciences companies that address tech debt through structural remediation can recover more than half of trapped technology value over five years.6 The barrier is rarely the will to modernize. It is the fear of breaking a validated system that has been in production since before the current head of quality was hired.

API-first architecture is the discipline that resolves this tension. When every legacy system boundary is a versioned, contract-tested, audit-logged interface, you can replace what sits behind that interface without renegotiating the integration with every downstream team. That is what makes wrap, replace, and strangle decisions tractable rather than terrifying.

Wrap, Replace, or Strangle: A Decision Framework

Three archetypes describe most legacy modernization decisions in regulated pharma. Each has a place, and choosing well matters more than the mechanics of any single implementation.

Wrap: Expose a validated system through a modern API without touching its guts

Wrapping means placing a thin API layer in front of an existing validated system, translating modern REST or GraphQL calls into whatever protocol the legacy system natively speaks. The underlying system remains untouched. Its validation status is preserved. The API becomes a new, validated interface that downstream consumers use instead of coupling directly to the legacy system.

Wrap when the underlying system still does its job well, the vendor is maintaining it, and the only real problem is that it is expensive or dangerous for downstream teams to integrate with. A common example is an older LIMS whose functional capabilities are fine but whose native integration story is a nightly SQL extract. A validated wrapping layer, exposed as a REST API with OpenAPI documentation, unlocks that data for scientists, analytics teams, and AI models without triggering a full LIMS replacement.

Replace: Retire and stand up a modern successor

Replace when the underlying platform is unsupported, cannot meet current regulatory expectations, or has become so operationally expensive that the risk of a controlled migration is lower than the risk of staying. A validated system that the vendor no longer patches is not a stable system. It is a delayed migration with a growing invoice.

Replacement is the highest-risk archetype in regulated pharma because it triggers full revalidation and often forces a data migration on top of the platform change. McKinsey’s operating-model work shows why many companies still choose it anyway: consolidation of multiple legacy systems into a single validated platform reduces long-term operational overhead and unlocks the kind of cross-domain data flows that drug-development timelines increasingly depend on.7

Strangle: Redirect traffic gradually until the legacy system is dead

The strangler fig pattern, named for the tropical vine that grows around a host tree until the host dies inside it, is the third and often most powerful option in regulated environments.8 An API facade sits in front of the legacy system. Every new capability is built behind that facade in a modern platform. As functionality moves, the facade routes calls to the new implementation rather than the old one. Eventually the legacy system carries only a handful of edge cases, and can be retired with dramatically less validation risk than a big-bang replacement.

Microsoft’s Azure architecture guidance describes the pattern as a controlled and phased approach that reduces migration risk because the existing application keeps functioning throughout.9 The strangler pattern is particularly well suited to regulated pharma because each incremental migration is small enough to validate on its own, and the legacy system remains authoritative for any function that has not yet moved. Enterprise big-bang implementations in healthcare have documented failure rates of 35 to 45 percent, often traced to poor clinical logic embedding and workflow-dependency gaps.5 Strangler-pattern migrations sidestep both.

WRAP

Best when the legacy system works but is hard to integrate with

Lowest risk. Preserves validated state. Buys time. Downside: the legacy system still runs the underlying process and eventually accumulates its own end-of-life issues.

REPLACE

Best when the platform is unsupported or misaligned with regulation

Highest strategic value. Triggers full revalidation and data migration. Requires strong executive sponsorship because the timeline is long and the disruption is visible.

STRANGLE

Best when the system does many things and cannot be replaced in one motion

Balances risk and progress. Each increment is validatable on its own. Requires disciplined API facade design and a route-decision layer that stays consistent across the whole transition.

SIT

The forgotten fourth option

Explicitly decide that a system is stable, non-strategic, and should be left alone. Documented deliberate inaction is a legitimate architectural choice and prevents accidental modernization scope creep.

The wrong question. Teams often ask “which pattern should we use for our LIMS modernization?” This treats the choice as a property of the system. It is not. The correct question is “which pattern for which capability?” A LIMS may be wrapped for read access, strangled for sample management, and left alone for regulatory reporting. Different capabilities live at different maturity levels and deserve different modernization paths.

Contract-First Design and Versioning for Long-Lived Integrations

Contract-first API design means the contract, typically an OpenAPI 3.1 or AsyncAPI specification, is the source of truth. Both sides of the integration build to the contract in parallel. Mocks are generated from the contract for early testing. Documentation is generated from the contract for downstream consumers. And critically for regulated environments, the contract becomes the artifact that ties validation evidence to a specific version of the interface.10

Analysts have found that teams sticking to contract-first practices deliver new endpoints 30 percent faster and meet reliability SLOs more often.10 The reason is not magic. It is that most integration bugs are caused by unstated assumptions on one side of the interface, and contract-first design forces those assumptions to be written down before either side is expensive to change.

The Sakara Digital perspective on contracts. A written API contract is the closest thing pharma has to a validated system-to-system SOP. When you treat the OpenAPI spec as a controlled document, review it with quality, and version it with the same rigor as a URS, you get the benefits of modern development speed without abandoning the discipline that makes pharma pharma. Treat the spec as validation evidence, not a developer artifact.

Versioning strategies that survive a decade

In pharma, an integration that survives ten years is not unusual. An integration that survives twenty is not rare. Your versioning strategy has to assume both. Semantic versioning is the standard vocabulary: MAJOR for breaking changes, MINOR for backward-compatible additions, PATCH for internal fixes.11 The design discipline that keeps a versioned API healthy over a long period is prioritizing backward compatibility so that MAJOR bumps are rare events, not annual occurrences. Additive changes such as new optional fields should never break existing contract expectations.11

Stripe’s hybrid approach, praised across the API-design literature, is worth studying for its applicability to regulated pharma. Stripe uses evolution for most changes, adding optional parameters and endpoints as needed, but issues full version releases only for significant breaking changes.11 The pattern maximizes stability for the vast majority of consumers while providing clear migration paths when architectural improvements require them.

The right deprecation cycle for regulated pharma is longer than the industry-standard 12 to 18 months. A conservative model is 24 months of active migration support before removal, with formal change-control notifications through each version transition. That timeline reflects the reality that many downstream integrations are validated systems in their own right and cannot chase a moving target every six months.

Change Type Version Impact Regulated Pharma Practice
New optional field on response MINOR Add without deprecation. Update spec, note in changelog, retest downstream integrations that opted into the new field.
New required field on request MAJOR Introduce as optional with a default, deprecate the old shape, promote to required only after all consumers have migrated.
Change to field semantics (units, enums, precision) MAJOR Introduce a new field with new name. Do not silently redefine existing fields. Old field continues to work through deprecation window.
Endpoint removal MAJOR Announce with 18-24 months lead time. Emit deprecation warnings in response headers. Track consumers via API gateway telemetry.
Auth scheme change MAJOR Run both schemes in parallel through a full transition window. Never force auth migration in the same release as a functional change.
Bug fix without behavioral change PATCH Release immediately, document in changelog, include in periodic revalidation summary rather than a full change-control cycle.

Validation Implications: Validating the API Layer

When APIs become the primary integration mechanism in a regulated environment, the validation model has to shift. The classic pattern of validating point-to-point interfaces one at a time does not scale, and it does not reflect where risk actually lives. In an API-first architecture, three things become the focus of validation attention: the contract itself, the tests that prove implementations conform to the contract, and the change-management process that governs contract evolution.

The contract as validation artifact

The OpenAPI or AsyncAPI specification is the closest thing an API-first architecture has to a functional specification. It defines every endpoint, every request and response shape, every error condition, every authentication requirement. Treating it as a validation deliverable means placing it under formal change control, requiring quality review before publication, and maintaining a version history that is traceable to specific system releases.

This is where the FDA’s Computer Software Assurance guidance changes the economics of API validation. Rather than proof-by-volume testing, CSA emphasizes risk-based, critical-thinking approaches: high-risk use cases get rigorous testing and strong evidence, while lower-risk areas can be justified with lighter testing and clear rationale.12 That maps naturally onto API validation because different endpoints carry very different risk. A GET endpoint returning historical batch data deserves different validation depth than a POST endpoint that creates an electronic signature.

Contract testing as the primary validation activity

Consumer-driven contract testing, most commonly implemented through Pact or similar tools, gives regulated teams a validation approach that is both rigorous and continuous.13 Every consumer of the API defines the interactions it depends on. Those contracts are published to a broker. The provider runs those contracts against every build. A breaking change fails the build before it can reach production.

For a regulated environment, contract testing offers something the classic integration-test approach never delivered: automatic proof that the interface behaves as specified for every consumer, on every build, with every result archived. Pact Broker’s can-i-deploy tool can gate deployments so that no producer change is released until all consumer contracts still verify.13 That is a validated quality gate, running continuously, with an audit trail as a natural side effect.

Real-world result. A hospital network implementing contract testing for patient record APIs, validating OpenAPI specs against HIPAA standards and running Pact tests between EHR and billing services, reduced audit findings by 85 percent.10 The same discipline applies cleanly to pharma APIs governed by 21 CFR Part 11 or Annex 11.

Handling breaking changes in a validated integration

Breaking changes are unavoidable in any long-lived API. The validation challenge is not preventing them but making them observable, reviewable, and reversible.

Common trap. Teams treat every API change as a change-control event. This is unsustainable and pushes teams to make changes outside change control to keep moving. The correct approach is a tiered change-control model where MAJOR changes trigger full change control, MINOR changes trigger lightweight review, and PATCH changes are covered by periodic revalidation summaries. This aligns with CSA’s risk-based philosophy and keeps the process honest.

Common Patterns: BFF, Event Streams, and GraphQL in Pharma

Three architectural patterns show up repeatedly in successful API-first pharma modernizations. Each solves a different class of integration problem, and each has particular resonance in regulated environments.

Backend for Frontend for lab platforms

The Backend for Frontend (BFF) pattern was introduced by Phil Calcado at SoundCloud and describes a custom backend service tailored to each client platform.14 Instead of every frontend and mobile client talking directly to a common backend, each client type talks to a dedicated BFF that aggregates and transforms data for its specific needs.

In pharma, the BFF pattern is a natural fit for lab platforms because scientific applications, dashboards, and mobile capture tools all need different views of the same underlying LIMS, ELN, and instrument data. A BFF for the bench scientist mobile app can pre-aggregate protocol steps and sample locations. A BFF for the QC dashboard can pull batch-level release metrics with completely different pagination and filtering. Both draw from the same underlying validated LIMS API, but each presents a client-appropriate surface.

The BFF pattern also gives teams a place to concentrate client-specific auth, tenant scoping, and audit logging without polluting the core LIMS API with client concerns. That separation matters for validation, because it means the core API can be validated once against its own contract, while each BFF is validated against the specific client workflows it serves.

Event streams for adverse events and manufacturing

Event-driven architectures shine in two pharma use cases that share a common property: the domain is naturally event-shaped. Adverse event detection and manufacturing execution are both continuous streams of things happening, not periodic batch processes.

For pharmacovigilance, real-time data from EHRs (via FHIR), claims, device telemetry, and patient reports can be ingested using Kafka or equivalent streaming platforms into a curated event store.15 Agentic frameworks then run continuously against those streams to detect signals, correlate reports, and escalate for review. The regulatory expectation of timely reporting is easier to meet when the underlying architecture is naturally continuous rather than batched.

For manufacturing, event-driven MES architectures produce electronic batch records as an event-driven evidence chain, so the record is generated by controlled execution rather than reconstructed after the fact.16 Every material issue, weight capture, step completion, inspection pass, deviation, hold, and release becomes a validated event in the stream. Downstream systems, from QC to release to regulatory reporting, consume the same event log rather than each maintaining its own copy.

GraphQL for clinical data warehouses

GraphQL is a query language and unified data-access layer that hides the internals of complex data stores behind a single endpoint. A client asks for exactly the fields it needs, in the exact shape it wants, and the server returns precisely that.17 For clinical data warehouses aggregating trial data across EDC, EHR, labs, imaging, and patient-reported outcomes, GraphQL provides a unifying surface that keeps downstream consumers decoupled from the physical storage layout.

Emerging work on healthcare-specific GraphQL, such as QL4MDR (a GraphQL query language for ISO 11179-based metadata repositories) and GraphQL-over-FHIR implementations, shows the pattern maturing in the healthcare interoperability space.17 Pharma is starting to follow, especially where data-warehouse consumers include internal analytics teams, external CROs, and regulatory submissions that all need different slices of the same trial data.

GraphQL is not the right answer everywhere. Its flexibility becomes a liability in high-volume machine-to-machine interfaces where consistent, cacheable REST responses are easier to validate and monitor. But for exploratory, client-shaped queries against a curated data warehouse, it is often the cleanest option.

Security and Audit for Regulated APIs

Security for regulated pharma APIs has three overlapping goals: proving who is calling, proving what they did, and proving that the system enforced the rules it was supposed to enforce. Modern API security stacks handle each of these with well-established patterns.

Authentication and authorization

OAuth 2.0 with OpenID Connect is the standard for user-facing APIs. Machine-to-machine calls typically use OAuth 2.0 client credentials flow or mutual TLS (mTLS) with certificate-based authentication.18 For most regulated pharma environments, combining these gives defense in depth: OAuth issues short-lived tokens with tightly scoped permissions, and mTLS confirms that the calling system is authorized at the network layer as well.

Identity lifecycle management is a separate concern that often gets underweighted. SCIM (System for Cross-domain Identity Management) automates the provisioning and deprovisioning of identities between systems, which matters in regulated environments because a user who leaves the company on Friday must lose API access by Monday morning.18 Manual provisioning is where audit findings live.

Audit logging as a first-class API concern

Every regulated API needs an audit log that captures user identity, timestamp, IP address, action performed, and any before-and-after data values, retained in encrypted, tamper-evident storage for the appropriate retention period.19 For clinical trial data, that retention can be twenty-five years.

21 CFR Part 11 Section 11.10(e) requires secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records.19 An API-first architecture makes this cleaner than the classic embedded-audit-inside-each-application approach because the API gateway can centralize audit capture across every endpoint, and downstream consumers inherit compliant audit logging without having to reimplement it.

Design principle. Every regulated API endpoint should answer three audit questions cleanly: who called it, what did they attempt to do, and what was the result. If any of these is ambiguous in your current audit design, the audit will not hold up under inspection. Fix the ambiguity before you write the endpoint documentation, not after.

Signature semantics on APIs

Electronic signature APIs deserve particular attention. All e-signature events must be logged with the signer’s identity, timestamp, and signature meaning as required by 21 CFR Part 11 Sections 11.50 and 11.100.19 When electronic signatures are exposed as an API rather than a screen interaction, the design has to carry every piece of information that would normally be captured in a UI: the intent of the signature, the record being signed, and cryptographic evidence that the signer authenticated at the moment of signing.

An API-First Maturity Model for Regulated Pharma

The Richardson Maturity Model provides a familiar vocabulary for describing how far an API has moved along REST principles, from Level 0 (a single HTTP endpoint that acts like RPC) to Level 3 (hypermedia-driven, with the API telling clients what to do next).20 Level 2 has become the practical standard for what most enterprises call RESTful.

The Richardson model is useful for API design, but it does not describe organizational maturity. For regulated pharma, we find a different five-stage model more useful because it captures the joint evolution of technology, validation practice, and governance.

1

Point-to-Point Integrations

Every integration is bespoke. There is no shared contract vocabulary. Integrations are validated one at a time and cannot be reused. This is the starting point for most pharma organizations. Modernization decisions are made per system without a broader strategy. There is no API catalog.

2

API Gateway with Documentation

An API gateway is standing up. OpenAPI documentation exists for critical services. There is a portal, even if it is thin. Authentication is centralized through OAuth or a single identity provider. Validation practice still treats each API as an independent system. Contract testing is aspirational.

3

Contract-First With Automated Testing

Contracts are the source of truth. Consumer-driven contract testing gates deployments. Every API is versioned, and version transitions are managed through published deprecation policies. Validation includes the contract as a controlled artifact. The organization has established governance around who can publish APIs and how.

4

API-as-Product With Ownership

Each significant API has a named product owner. APIs have roadmaps, adoption metrics, and success KPIs. The organization can articulate which APIs are strategic and which are commodity. Legacy systems are actively being strangled behind well-designed facades. Modernization decisions are made in service of API strategy, not the other way around.

5

API-Driven Composable Enterprise

New capabilities are assembled from existing APIs rather than built from scratch. The API portfolio is a strategic asset that determines what the company can do quickly. AI agents and analytics workloads consume APIs as first-class citizens. Validation and governance are automated to the point where speed and compliance are no longer in tension.

Most mid-cap pharma organizations sit somewhere between Stage 1 and Stage 2. The move from Stage 2 to Stage 3 is the hardest and highest-value transition in the model, because it requires a genuine shift in how validation, quality, and engineering work together. Stages 4 and 5 are aspirational for now, though a handful of global pharma companies are visibly making the move.

Reference Architecture Patterns

Three reference architectures come up repeatedly in successful API-first pharma modernizations. Each targets a specific class of integration challenge, and each incorporates the security, validation, and governance considerations discussed above.

Pattern A: Wrapped LIMS with a BFF layer

A validated LIMS remains the system of record for sample and result data. A REST API layer is placed in front of the LIMS, exposing sample queries, result submissions, and status updates through a well-documented OpenAPI 3.1 contract. Client-specific BFFs sit above this API, one for the QC dashboard, one for the bench scientist mobile app, one for regulatory reporting. Each BFF authenticates through the corporate identity provider and passes signed audit events to a centralized audit log.

The LIMS itself changes rarely. When a new scientific application is needed, it is built as a new BFF against the same core LIMS API. Validation focuses on the API contract and the audit logging, not on rebuilding client-side integrations from scratch. This pattern preserves the validated LIMS state while unlocking modern application development on top.

Pattern B: Event-driven pharmacovigilance stream

Adverse event data enters the pipeline from multiple sources: EHR FHIR endpoints, patient reports through a public API, call center intake, and device telemetry.21 Each source publishes to a Kafka topic through a validated ingestion service. Downstream consumers include a signal detection service, a case management platform, and a regulatory reporting service, each subscribing to the topics it needs.

The event log is the audit trail. Every event is immutable, timestamped, and cryptographically signed. Consumer services can be added, changed, or replaced without disrupting other consumers. When the FDA or EMA asks how a specific case was handled, the answer is a reconstruction of the events, not a hunt through five different systems for consistent timestamps.

Pattern C: GraphQL-fronted clinical data warehouse

A clinical data warehouse aggregates trial data across EDC, EHR (via FHIR), central labs, imaging, and patient-reported outcomes. Direct SQL access is deprecated. Instead, a GraphQL layer exposes a curated schema aligned to CDISC standards and internal metadata.22 Downstream consumers, whether internal analytics, CROs, or regulatory submission preparation, query the same GraphQL endpoint with role-scoped permissions.

The GraphQL schema is the validation artifact. Field-level access control is enforced by the layer. Every query is logged with the user, the timestamp, the specific fields requested, and the row count returned. Data provenance is preserved as GraphQL resolvers add lineage metadata to every field, satisfying data-integrity expectations without requiring downstream consumers to trace lineage themselves.

Cross-pattern considerations

These three patterns are rarely deployed in isolation. A mature pharma organization typically runs all three simultaneously: BFFs for lab and clinical applications, event streams for adverse events and manufacturing telemetry, and GraphQL for warehouse queries. The connecting tissue is the API gateway, the identity provider, and the audit-logging backbone that every pattern feeds. Those three shared services are what keep the architecture coherent as it grows and what make new capabilities cheap to add.

Investment in the shared backbone tends to lag investment in individual applications. That is where architectural discipline pays off most visibly. Organizations that treat the gateway, identity, and audit services as first-class products with dedicated ownership see their per-application integration costs fall by the second or third rollout. Organizations that let each application team build its own version end up validating the same concerns repeatedly and never realizing the compounding benefit of an API-first approach.

Where SD sees these patterns win. The best-executed API-first modernizations we see are not the ones with the most sophisticated technology stacks. They are the ones where the API contract is treated as a controlled document, where product ownership is clear, and where quality is embedded early rather than bolted on late. The technology is the easy part. The governance is where the differentiation lives.

Conclusion

API-first modernization in regulated pharma is not a technology bet. It is a discipline bet. The technology has been available and well documented for years. What separates the organizations that make progress from the ones that stall is whether they treat APIs as controlled products with owners, contracts, and lifecycle management, or as one-off engineering artifacts that nobody quite owns after go-live. The regulatory environment now supports the discipline: FDA’s Computer Software Assurance guidance, ISPE’s updated GAMP 5 second edition, and EMA’s continued modernization of expectations all point toward risk-based, evidence-driven validation approaches that pair naturally with contract-first API design.

The specific choices around wrap, replace, or strangle are always situational, but the underlying principle is stable. Preserve validated state where you can. Move deliberately where you must. Make every system boundary a versioned, tested, audit-logged contract, and the rest of the modernization decisions become easier because you are no longer risking downstream integrations every time you change a backend.

Sakara Digital works with pharma and biotech organizations designing API-first architectures in validated environments, defining contract governance models that satisfy both engineering and quality, and building the operational discipline that makes long-lived integrations manageable rather than perilous. If you are working through a legacy modernization decision and want an independent perspective on where an API-first approach fits, we are happy to have that conversation.